Gordian Biotechnology

Gordian Biotechnology is a South San Francisco-based biotechnology company founded in 2018 with a mission to cure age-related diseases by accelerating the translation of promising therapeutics into clinical trials within months rather than years. The company's proprietary in vivo drug discovery platform — comprising Patient Avatars, Mosaic Screening, and Pythia transcriptomics — validates hundreds of therapeutic targets simultaneously in living animal models that closely represent human patients, generating causal data in the context of chronic conditions such as heart failure, obesity, and chronic kidney disease. This high-throughput approach has already screened more than 500 targets across cardio-renal-metabolic indications and has attracted partnerships with Pfizer. Co-founded by CEO Francisco LePort and CSO Martin Borch Jensen, Gordian operates a pipeline of high-confidence drug programs anchored in its scalable in vivo screening engine.